Sun Pharma Declares Net Profit Of Rs 1,984 Cr In Q4 Results

Sun Pharmaceuticals announced its Q4 results on Friday and declared a consolidated profit of Rs 1984, compared to a net loss of Rs 2,277 crore in the year's corresponding period. During the month of January- March, the company records a growth of 15.7 per cent. 

According to the results, the pharma company had reported a net loss of Rs 2,277 crore in the January-March quarter of last year. 

The Q4 results declared that  EBITDA at Rs 28,021 million, up 19.7 per cent vs Q4 last year. EBITDA margin for Q4 at 25.6 per cent vs 24.8 per cent for Q4 last year. 

These results were taken on record by the Board of Directors at a meeting held today. The Board has proposed a final dividend of Rs. 4.00 per share for the year FY23. This is in addition to the interim dividend of Rs. 7.5 per share paid in FY23, taking the total dividend for FY23 to Rs. 11.5 per share compared to Rs. 10 per share for FY22. 

Dilip Shanghvi, Managing Director of the Company said, “I am pleased with well-rounded growth demonstrated in FY23 by the company. Several of our businesses including Specialty, India and Emerging markets have continued to progress well. Our Specialty business remains on growth path and we are committed to continue scaling it up. The acquisition of Concert helps further strengthen our portfolio in dermatology. I believe deuruxolitinib can become a leading product to address highly unmet need in alopecia areata patients."

As the market was expecting good results, Shares of Sun Pharma closed 2.32 per cent higher on Friday at Rs 966.95 at NSE.